Willingness-to-pay per quality-adjusted life year of patients with psoriasis: A study in Vietnam

Dinh Hoang Yen; Nguyen Trong Hao; Nguyen Thuy Hang

doi:10.59294/HIUJS.VOL.7.2024.683

Từ khóa:

WTP/QALY, EQ-5D-5L, Dermato-Venereology hospital, related factors

Tóm tắt

Background: The chronic nature and frequent recurrence of psoriasis reduce patients' quality of life and increase treatment costs. This study aimed to estimate the willingness-to-pay (WTP) per quality-adjusted life-year (QALY) of psoriasis patients in Vietnam. Patients and methods: A cross-sectional study was conducted based on face-to-face interviews with psoriasis patients at Ho Chi Minh City (HCMC) Hospital of Dermato-Venereology. The Euro Quality of Life 5-Dimension 5-Level (EQ-5D-5L) questionnaire was used, and questions about WTP were asked. Factors related to WTP per QALY were analysed statistically. Results: A total of 310 psoriasis patients (58.4% males; mean age of 48.84±16.27 years) were included. The mean disease and treatment durations were 11.51±9.82 and 9.69±8.87 years, respectively. The mean health-related quality of life was 0.787±0.128, and WTP/QALY was 7,726.86±4,506.82 USD (179,100,000±104,463,500 VND). Patients with university/college degrees had a significantly higher WTP/QALY (10,666.60 USD - 247.24 million VND) than patients with high school or under high school education (8,440.44 and 6,638.38 USD - 195.64 million and 153.87 million VND, p<0.05). There was a significant negative correlation between WTP/QALY and age (r=-0.247, p=0.000). Conclusions: The WTP per QALY of psoriasis patients was almost 3 times higher than GDP per capita of Vietnam in 2018. Education level, health-related quality of life and age are associated with WTP/QALY.

Abstract

Background: The chronic nature and frequent recurrence of psoriasis reduce patients' quality of life and increase treatment costs. This study aimed to estimate the willingness-to-pay (WTP) per quality-adjusted life-year (QALY) of psoriasis patients in Vietnam. Patients and methods: A cross-sectional study was conducted based on face-to-face interviews with psoriasis patients at Ho Chi Minh City (HCMC) Hospital of Dermato-Venereology. The Euro Quality of Life 5-Dimension 5-Level (EQ-5D-5L) questionnaire was used, and questions about WTP were asked. Factors related to WTP per QALY were analysed statistically. Results: A total of 310 psoriasis patients (58.4% males; mean age of 48.84±16.27 years) were included. The mean disease and treatment durations were 11.51±9.82 and 9.69±8.87 years, respectively. The mean health-related quality of life was 0.787±0.128, and WTP/QALY was 7,726.86±4,506.82 USD (179,100,000±104,463,500 VND). Patients with university/college degrees had a significantly higher WTP/QALY (10,666.60 USD - 247.24 million VND) than patients with high school or under high school education (8,440.44 and 6,638.38 USD - 195.64 million and 153.87 million VND, p<0.05). There was a significant negative correlation between WTP/QALY and age (r=-0.247, p=0.000). Conclusions: The WTP per QALY of psoriasis patients was almost 3 times higher than GDP per capita of Vietnam in 2018. Education level, health-related quality of life and age are associated with WTP/QALY.

Tài liệu tham khảo

[1] A. Lowes, Bowcock, A. M. and Krueger, J. G. , "Pathogenesis and therapy of psoriasis," (in z), Nature, vol. 445, no. 7130, p. 866, 2007.

DOI: https://doi.org/10.1038/nature05663

[2] R. Saraceno, Gramiccia, T.,… and Chimenti, S., "Calcipotriene/betamethasone in the treatment of psoriasis: a review article," (in y), Expert opinion on pharmacotherapy, vol. 10, no. 14, pp. 2357-2365, 2009.

DOI: https://doi.org/10.1517/14656560903198960

[3] R. Parisi, Symmons, D. P., Griffiths and Ashcroft, D. M. , "Global epidemiology of psoriasis: a systematic review of incidence and prevalence," (in x), Journal of Investigative Dermatology, vol. 133, no. 2, pp. 377-385, 2013.

DOI: https://doi.org/10.1038/jid.2012.339

[4] D. W. Miller and Feldman, S. R. , "Cost-effectiveness of moderate-to-severe psoriasis treatment," (in w), Expert opinion on pharmacotherapy, vol. 7, no. 2, pp. 157-167, 2006.

DOI: https://doi.org/10.1517/14656566.7.2.157

[5] N. Thuy, Kinh tế dược trong thực hành lâm sàng. Ho Chi MInh City: Vietnam National University Press (in v), 2017.

[6] J. Brazier, Roberts, J. and Deverill, M., "The estimation of a preference-based measure of health from the SF-36," (in u), Journal of health economics, vol. 21, no. 2, pp. 271-292, 2002.

DOI: https://doi.org/10.1016/S0167-6296(01)00130-8

[7] W. J. Furlong, Feeny, D. H. and Barr, R. D., "The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies," (in t), Annals of medicine, vol. 33, no. 5, pp. 375-384, 2001.

DOI: https://doi.org/10.3109/07853890109002092

[8] G. Richardson and Manca, A., "Calculation of quality adjusted life years in the published literature: A review of methodology and transparency," (in s), Health economics, vol. 13, no. 12, pp. 1203-1210, 2004.

DOI: https://doi.org/10.1002/hec.901

[9] A. G. O. T. A. Szende, EQ-5D value sets: Inventory, comparative review and user guide. Berlin, Germany, Springer: M. Oppe, & N. J. Devlin (Eds.) (in r), 2007.

[10] J. Charan and Biswas, T.,, "How to calculate sample size for different study designs in medical research?," (in n), Indian journal of psychological medicine, vol. 35, no. 2, p. 121, 2013.

DOI: https://doi.org/10.4103/0253-7176.116232

[11] J. Charan, R. Kaur, P. Bhardwaj,… and S. Misra, "Sample size calculation in medical research: A primer," Annals of the National Academy of Medical Sciences (India), vol. 57, no. 02, pp. 074-080, 2021.

DOI: https://doi.org/10.1055/s-0040-1722104

[12] L. H. Nguyen, B. X. Tran,… and C. A. Latkin, "Quality of life profile of general Vietnamese population using EQ-5D-5L," Health and quality of life outcomes, vol. 15, pp. 1-13, 2017.

DOI: https://doi.org/10.1186/s12955-017-0771-0

[13] S. J. Whitehead and Ali, S., "Health outcomes in economic evaluation: The QALY and utilities," (in p), British medical bulletin, vol. 96, no. 1, pp. 5-21, 2010.

[14] A. Szende, M. Oppe, and N. J. Devlin, EQ-5D value sets: Inventory, comparative review and user guide. Springer, 2007.

DOI: https://doi.org/10.1007/1-4020-5511-0

[15] S. J. Whitehead and S. J. B. m. b. Ali, "Health outcomes in economic evaluation: the QALY and utilities," British medical bulletin. , vol. 96, no. 1, pp. 5-21, 2010.

DOI: https://doi.org/10.1093/bmb/ldq033

[16] W. Vickrey, "Counterspeculation, auctions, and competitive sealed tenders," (in o), The Journal of finance, vol. 16, no. 1, pp. 8-37, 1961.

DOI: https://doi.org/10.1111/j.1540-6261.1961.tb02789.x

[17] J. Martín-Fernández, Polentinos-Castro,… and García-Pérez, S., "Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences," (in i), BMC health services research, vol. 14, no. 1, p. 287, 2014.

DOI: https://doi.org/10.1186/1472-6963-14-287

[18] M. D. Fanni Rencz, Ahmad Moradi, M. D. and Gulácsi, L., "Health status and quality of life in patients with psoriasis: An Iranian cross-sectional survey," (in m), Archives of Iranian medicine, vol. 18, no. 3, p. 153, 2015.

[19] W. C. Ko, Tsai, T. F. and Tang, C. H., "Health state utility, willingness to pay, and quality of lifeamong Taiwanese patients with psoriasis," (in l), Dermatologica Sinica, vol. 34, no. 4, pp. 185- 191, 2016.

DOI: https://doi.org/10.1016/j.dsi.2016.05.004

[20] K. Dierick and Rose, A.,, "Assessing willigness to pay among psoriasis and psoriatic arthritis patients," (in k), Value in Health, vol. 17, no. 7, p. A387, 2014.

DOI: https://doi.org/10.1016/j.jval.2014.08.2652

[21] A. Bobinac, Van Exel, N. J. A.,... and Brouwer, W. B. ,, "Willingness to pay for a quality‐Adjusted Life‐Year: The Individual Perspective," (in j), Value in Health, vol. 13, no. 8, pp. 1046-1055, 2010.

DOI: https://doi.org/10.1111/j.1524-4733.2010.00781.x

[22] L. Lundberg, Johannesson, M.,… and Lindberg, M., "Quality of life, health‐state utilities and willingness to pay in patients with psoriasis and atopic eczema," (in h), British Journal of Dermatology, vol. 141, no. 6, pp. 1067-1075, 1999.

DOI: https://doi.org/10.1046/j.1365-2133.1999.03207.x

[23] A. Y. Finlay and Coles, E., "The effect of severe psoriasis on the quality of life of 369 patients," (in g), British Journal of Dermatology, vol. 132, no. 2, pp. 236-244, 1995.

DOI: https://doi.org/10.1111/j.1365-2133.1995.tb05019.x

[24] K. Blumenschein and Johannesson, M.,, "Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma," (in f), Annals of allergy, asthma & immunology, vol. 80, no. 2, pp. 236-244, 1998.

DOI: https://doi.org/10.1016/S1081-1206(10)62954-7

[25] Nguyen TTT, "Analysis of willingness to pay for a quality-adjusted life year in outpatients with cardiovascular diseases at heart institute in ho chi minh city," University of Medicine and Pharmacy, Ho Chi Minh City, 2016.

[26] M. A. Radtke, Schäfer, I.,... and Augustin, M.,, "Willingness‐to‐pay and quality of life in patients with vitiligo," (in d), British Journal of Dermatology, vol. 161, no. 1, pp. 134-139, 2009.

DOI: https://doi.org/10.1111/j.1365-2133.2009.09091.x

[27] W. B. Van Den Hout, De Jong, Z.,... and Vliet Vlieland, T. P.,, "Cost‐utility and cost‐effectiveness analyses of a long‐term, high‐intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis," (in c), Arthritis Care & Research, vol. 53, no. 1, pp. 39-47, 2005.

DOI: https://doi.org/10.1002/art.20903

[28] Azimatun Noor Aizuddin et al, "Factors influencing willingness to pay for healthcare," (in b), BMC Public Health, vol. 12, p. A37, 2012.

DOI: https://doi.org/10.1186/1471-2458-12-S2-A37